文献速递呼吸道感染

实时肺炎临床决策支持的阶梯楔形集群对照试验

A Pragmatic, Stepped-Wedge, Cluster-controlled Clinical Trial of Real-Time Pneumonia Clinical Decision Support.
PubMed 文献 · Am J Respir Crit Care Med · 2022-01-01

在16家社区医院开展实用型阶梯楔形集群对照试验,评估嵌入电子健康记录的实时肺炎临床决策支持系统ePNa。纳入6848例急诊成人肺炎患者,部署后30天全因死亡率调整OR为0.62,抗菌药物处方一致性提高,急诊离院率增加而7天再入院率无变化。

要点

  • ePNa部署与30天全因死亡率降低相关,调整OR 0.62。
  • ePNa一致性抗菌药物处方从83.5%升至90.2%。
  • 急诊离院率从29.2%升至46.9%,7天二次入院率无变化。

核心结论

  • ePNa部署与护理流程改善和死亡率降低相关。

研究设计与样本

  • 实用型、阶梯楔形、集群对照试验,在16家社区医院以2个月间隔部署ePNa。
  • 纳入3年内经ICD-10出院编码确认且胸部影像证实的急诊成人肺炎患者6848例。

主要发现

  • 患者中位年龄67岁(IQR 50-79),48%为女性,64.8%住院。
  • 未调整死亡率部署前8.6%,部署后4.8%。
  • 调整疾病严重度并以医院集群为随机效应,部署后30天全因死亡率调整OR 0.62(0.49-0.79;P < 0.001)。
  • ePNa一致性抗菌药物处方从83.5%升至90.2%(P < 0.001)。
  • 急诊到首次抗菌药物平均时间从159.4分钟(156.9-161.9)降至150.9分钟(144.1-157.8)(P < 0.001)。

关键数值与推荐

  • ePNa用于指导诊断、风险分层、微生物学检查、照护地点和抗菌药物治疗。
  • 急诊离院率从29.2%升至46.9%,7天二次入院率5.2% vs 6.1%无变化。
  • ePNa在67%的合格患者中被急诊临床医生使用。

临床怎么用

  • 在社区医院急诊肺炎诊疗中部署实时电子临床决策支持可能改善流程并降低死亡率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Care of emergency department (ED) patients with pneumonia can be challenging. Clinical decision support may decrease unnecessary variation and improve care. Objectives: To report patient outcomes and processes of care after deployment of electronic pneumonia clinical decision support (ePNa): a comprehensive, open loop, real-time clinical decision support embedded within the electronic health record. Methods: We conducted a pragmatic, stepped-wedge, cluster-controlled trial with deployment at 2-month intervals in 16 community hospitals. ePNa extracts real-time and historical data to guide diagnosis, risk stratification, microbiological studies, site of care, and antibiotic therapy. We included all adult ED patients with pneumonia over the course of 3 years identified by International Classification of Diseases, 10th Revision discharge coding confirmed by chest imaging. Measurements and Main Results: The median age of the 6,848 patients was 67 years (interquartile range, 50-79), and 48% were female; 64.8% were hospital admitted. Unadjusted mortality was 8.6% before and 4.8% after deployment. A mixed effects logistic regression model adjusting for severity of illness with hospital cluster as the random effect showed an adjusted odds ratio of 0.62 (0.49-0.79; P < 0.001) for 30-day all-cause mortality after deployment. Lower mortality was consistent across hospital clusters. ePNa-concordant antibiotic prescribing increased from 83.5% to 90.2% (P < 0.001). The mean time from ED admission to first antibiotic was 159.4 (156.9-161.9) minutes at baseline and 150.9 (144.1-157.8) minutes after deployment (P < 0.001). Outpatient disposition from the ED increased from 29.2% to 46.9%, whereas 7-day secondary hospital admission was unchanged (5.2% vs. 6.1%). ePNa was used by ED clinicians in 67% of eligible patients. Conclusions: ePNa deployment was associated with improved processes of care and lower mortality. Clinical trial registered with www.clinicaltrials.gov (NCT03358342).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Dean NC, Vines CG, Carr JR, et al. A Pragmatic, Stepped-Wedge, Cluster-controlled Clinical Trial of Real-Time Pneumonia Clinical Decision Support. Am J Respir Crit Care Med. 2022. PMID: 35258444. doi:10.1164/rccm.202109-2092OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。